Founded in 2019 and based in Durham, North Carolina, Tavros Therapeutics is a precision oncology platform company that leverages its proprietary platform and map of synthetic lethal relationships to develop small-molecule drug candidates. The company's management team consists of experienced entrepreneurs with expertise in functional genomics, tumor genetics, and drug discovery. Tavros Therapeutics is at the forefront of targeted therapies that exploit tumors' genetic vulnerabilities, with a highly innovative pipeline of category-defining drugs.